Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15982310 | 0.87 | ALDH1A1 (0.54) | MEN1KMT2AKCNH2SLC6A3SIGMAR1 | |
| SCHEMBL4486515 | 0.86 | ALDH1A1 (0.62) | MEN1KMT2AKCNH2SLC6A3SIGMAR1 | |
| SCHEMBL9610820 | 0.85 | EBP (0.55) | MEN1KMT2AKCNH2SIGMAR1HTR2A | |
| SCHEMBL6550220 | 0.85 | SIGMAR1 (0.60) | MEN1KMT2AKCNH2SIGMAR1HTR1A | |
| SCHEMBL7264546 | 0.84 | SLC6A3 (0.83) | MEN1KMT2AKCNH2SLC6A3SIGMAR1 | |
| SCHEMBL6056974 | 0.84 | SLC6A3 (0.83) | MEN1KMT2AKCNH2SLC6A3SIGMAR1 | |
| SCHEMBL14407778 | 0.84 | SLC6A3 (0.83) | MEN1KMT2AKCNH2SLC6A3SIGMAR1 | |
| SCHEMBL13150782 | 0.84 | SLC6A3 (0.83) | MEN1KMT2AKCNH2SLC6A3SIGMAR1 | |
| SCHEMBL10900913 | 0.84 | MEN1 (0.62) | MEN1KMT2AKCNH2SLC6A3SIGMAR1 | |
| SCHEMBL4485401 | 0.82 | SLC6A3 (0.62) | MEN1KMT2AKCNH2SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| CN-119816484-A | Novel piperazine derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2025-04-11 | — | — | CN | disclosed |
| WO-2024043334-A1 | NOVEL PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | MEN1 3362/4885KMT2A 1705/4885KCNH2 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.